Literature DB >> 20797987

International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes.

Sean P Collins1, Peter S Pang, Christopher J Lindsell, Demetrios N Kyriacou, Alan B Storrow, Judd E Hollander, J Douglas Kirk, Chadwick D Miller, Richard Nowak, W Frank Peacock, Miguel Tavares, Alexandre Mebazaa, Mihai Gheorghiade.   

Abstract

AIMS: Results from investigations in one area of the world may not translate to another if patient characteristics and practices differ. We examine differences in the presentation and management of emergency department (ED) patients with dyspnoea from acute heart failure syndromes (AHFS) between the USA, Western Europe, and Eastern Europe. METHODS AND
RESULTS: The URGENT Dyspnoea study was a multinational prospective observational study of dyspnoeic ED patients with AHFS from 18 countries. Acute heart failure syndrome patients from the USA and Western and Eastern Europe underwent dyspnoea assessments within 1 h of the first physician evaluation. Patient characteristics, evaluation, and treatments were compared between geographical regions using analysis of variance and χ(2) tests. Four hundred and ninety-three patients with AHFS met the inclusion criteria. Participants in the USA were more frequently non-white, younger, on chronic beta-blocker therapy, and with an ejection fraction ≤40% when compared with Eastern and Western Europe. Patients from Eastern Europe were more likely to present with de novo heart failure and have ischaemic electrocardiogram changes. Pulmonary oedema was more common on chest radiograph in Western Europe, but natriuretic peptide levels were elevated in all three regions. Diuretic use was similar across all the regions. Intravenous nitroglycerin was used more frequently in Eastern (32.8%) and Western Europe (24.4%) compared with the USA (2.5%).
CONCLUSION: International differences in AHFS presentations and management between regions suggest results from clinical trials in one region may not translate directly to another. These differences should be considered when designing trials and interpreting the results from clinical investigations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797987      PMCID: PMC2981015          DOI: 10.1093/eurjhf/hfq133

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  22 in total

1.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Gregg C Fonarow; J Thomas Heywood; Paul A Heidenreich; Margarita Lopatin; Clyde W Yancy
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

2.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema.

Authors:  G Cotter; E Metzkor; E Kaluski; Z Faigenberg; R Miller; A Simovitz; O Shaham; D Marghitay; M Koren; A Blatt; Y Moshkovitz; R Zaidenstein; A Golik
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

3.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

4.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

5.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Authors:  Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

6.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

Authors:  Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

7.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Authors:  John J V McMurray; John R Teerlink; Gadi Cotter; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

8.  Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial.

Authors:  Bertram Pitt; Faiez Zannad; Mihai Gheorghiade; Felipe Martínez; Thomas E Love; Casey Daniel; Ali Ahmed
Journal:  Int J Cardiol       Date:  2009-04-15       Impact factor: 4.164

9.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

10.  Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis.

Authors:  Phillip Levy; Scott Compton; Robert Welch; George Delgado; Alison Jennett; Neelima Penugonda; Robert Dunne; Robert Zalenski
Journal:  Ann Emerg Med       Date:  2007-05-23       Impact factor: 5.721

View more
  24 in total

1.  Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy.

Authors:  Sean P Collins; Christopher J Lindsell; Alan B Storrow; Gregory J Fermann; Phillip D Levy; Peter S Pang; Neal Weintraub; W Frank Peacock; Douglas B Sawyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 2.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  Patient selection in heart failure with preserved ejection fraction clinical trials.

Authors:  Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam
Journal:  J Am Coll Cardiol       Date:  2015-04-28       Impact factor: 24.094

Review 4.  Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes.

Authors:  Andrew P Ambrosy; Mihai Gheorghiade; Ovidiu Chioncel; Robert J Mentz; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2014-12

5.  Pulmonary Oedema-Therapeutic Targets.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Mihai Gheorghiade; Gerasimos Filippatos
Journal:  Card Fail Rev       Date:  2015-04

6.  How to Improve Time to Diagnosis in Acute Heart Failure - Clinical Signs and Chest X-ray.

Authors:  Christopher J Allen; Kaushik Guha; Rakesh Sharma
Journal:  Card Fail Rev       Date:  2015-10

Review 7.  End points in heart failure-are we doing it right?

Authors:  Luxitaa Goenka; Melvin George; Sandhiya Selvarajan
Journal:  Eur J Clin Pharmacol       Date:  2017-03-09       Impact factor: 2.953

8.  International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.

Authors:  Robert J Mentz; Gad Cotter; John G F Cleland; Susanna R Stevens; Karen Chiswell; Beth A Davison; John R Teerlink; Marco Metra; Adriaan A Voors; Liliana Grinfeld; Mikhail Ruda; Viacheslav Mareev; Chaim Lotan; Daniel M Bloomfield; Mona Fiuzat; Michael M Givertz; Piotr Ponikowski; Barry M Massie; Christopher M O'Connor
Journal:  Eur J Heart Fail       Date:  2014-04-25       Impact factor: 15.534

Review 9.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

10.  Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure.

Authors:  Luiz Carlos Passos; Márcio Galvão Oliveira; Andre Rodrigues Duraes; Thiago Moreira Trindade; Andréa Cristina Costa Barbosa
Journal:  Int J Clin Pharm       Date:  2016-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.